Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation
- aDepartment of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208;
- bInternational Institute for Nanotechnology, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208; and
- cDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, 676 North St. Clair Street, Suite 1600, Chicago, IL 60611
See allHide authors and affiliations
Edited by Rakesh K. Jain, Harvard Medical School and Massachusetts General Hospital, Boston, MA, and approved June 6, 2012 (received for review November 22, 2011)

Abstract
Topical application of nucleic acids offers many potential therapeutic advantages for suppressing genes in the skin, and potentially for systemic gene delivery. However, the epidermal barrier typically precludes entry of gene-suppressing therapy unless the barrier is disrupted. We now show that spherical nucleic acid nanoparticle conjugates (SNA-NCs), gold cores surrounded by a dense shell of highly oriented, covalently immobilized siRNA, freely penetrate almost 100% of keratinocytes in vitro, mouse skin, and human epidermis within hours after application. Significantly, these structures can be delivered in a commercial moisturizer or phosphate-buffered saline, and do not require barrier disruption or transfection agents, such as liposomes, peptides, or viruses. SNA-NCs targeting epidermal growth factor receptor (EGFR), an important gene for epidermal homeostasis, are > 100-fold more potent and suppress longer than siRNA delivered with commercial lipid agents in cultured keratinocytes. Topical delivery of 1.5 uM EGFR siRNA (50 nM SNA-NCs) for 3 wk to hairless mouse skin almost completely abolishes EGFR expression, suppresses downstream ERK phosphorylation, and reduces epidermal thickness by almost 40%. Similarly, EGFR mRNA in human skin equivalents is reduced by 52% after 60 h of treatment with 25 nM EGFR SNA-NCs. Treated skin shows no clinical or histological evidence of toxicity. No cytokine activation in mouse blood or tissue samples is observed, and after 3 wk of topical skin treatment, the SNA structures are virtually undetectable in internal organs. SNA conjugates may be promising agents for personalized, topically delivered gene therapy of cutaneous tumors, skin inflammation, and dominant negative genetic skin disorders.
Footnotes
- ↵1To whom correspondence may be addressed. E-mail: apaller{at}northwestern.edu or chadnano{at}northwestern.edu.
Author contributions: D.Z., D.A.G., D.L.C., C.A.M., and A.S.P. designed research; D.Z., D.A.G., D.L.C., M.D.M., X.Q.W., and H.I. performed research; H.I. contributed new reagents/analytic tools; D.Z., D.A.G., D.L.C., M.D.M., X.Q.W., and A.S.P. analyzed data; and D.Z., D.A.G., D.L.C., X.Q.W., C.A.M., and A.S.P. wrote the paper.
Conflict of interest statement: This technology has been licensed from Northwestern University by AuraSense Therapeutics, LLC. C.A.M., A.S.P., and D.A.G. have financial interests in AuraSense Therapeutics, LLC.
This article is a PNAS Direct Submission.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1118425109/-/DCSupplemental.
Citation Manager Formats
Article Classifications
- Biological Sciences
- Applied Biological Sciences
- Physical Sciences
- Chemistry